04.01.2024 15:10:21
|
INOVIO Enters Clinical Collaboration And Supply Agreement With Coherus BioSciences
(RTTNews) - INOVIO (INO) announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. (CHRS) to evaluate the combination of INO-3112 and LOQTORZI as a potential treatment for patients with locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squamous cell carcinoma, a type of head and neck cancer commonly known as throat cancer. Coherus will provide LOQTORZI for a Phase 3 clinical trial to be conducted by INOVIO.
"We are delighted to be partnering with INOVIO on the development of the toripalimab/INO-3112 combination in HPV-related OPSCC, a tumor type that is synergistic to the current toripalimab indication in R/P NPC," said Rosh Dias, Chief Medical Officer at Coherus.
For More Such Health News, visit rttnews.com.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Coherus BioSciences Incmehr Nachrichten
05.11.24 |
Ausblick: Coherus BioSciences stellt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
07.08.24 |
Ausblick: Coherus BioSciences öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) |